Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01)

This grant invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium.

Goals of the SCLC Consortium pertinent to this FOA are:

1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity;

2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations;

3) to understand clinical resistance to drug and radiation therapy and its rapid development

Funding: $450,000 per year 

Duration: 5 years

Research Authority due date: 10 days prior to submission

LOI (encouraged) due dates: 12.10.19, 11.2.20, 12.10.20, 11.2.21, 12.10.21, 11.2.22

Full proposal due dates:  12.11.19, 11.3.20, 12.11.20, 11.3.21, 12.11.21, 11.3.22